The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) showed that canakinumab, a human therapeutic monoclonal antibody targeting interleukin (IL)-1β, significantly reduced major adverse cardiovascular events (MACE) without affecting lipid levels in patients with a history of acute myocardial infarction with elevated C-reactive protein (CRP). This evidence concerns the gene CRP and myocardial infarction.